Premium
Serum Cytokine Levels of Interleukin‐1β, ‐6, ‐8, Tumour Necrosis Factor‐α and Vascular Endothelial Growth Factor in Breast Cancer Patients Treated with Tamoxifen and Supplemented with Co‐Enzyme Q 10 , Riboflavin and Niacin
Author(s) -
Premkumar Vummidi Giridhar,
Yuvaraj Srinivasan,
Vijayasarathy Kothandaraman,
Gangadaran Sitthu Govindaswamy Dinakaran,
Sachdanandam Panchanatham
Publication year - 2007
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/j.1742-7843.2007.00065.x
Subject(s) - medicine , cytokine , breast cancer , tamoxifen , vascular endothelial growth factor , cancer , tumor necrosis factor alpha , endocrinology , gastroenterology , oncology , vegf receptors
The prognostic significance of supplementing co‐enzyme Q 10 (CoQ 10 ), riboflavin and niacin (CoRN) along with tamoxifen to breast cancer patients was evaluated by measuring the serum cytokine levels of interleukin (IL)‐1β, IL‐6, IL‐8, tumour necrosis factor α (TNF‐α) and vascular endothelial growth factor. In the present study, 84 breast cancer patients were randomized to receive a daily supplement of CoQ 10 100 mg, riboflavin 10 mg and niacin 50 mg, one dosage per day along with tamoxifen 10 mg twice a day. Serum cytokine levels were elevated in untreated breast cancer patients (Group II) and significantly reduced after tamoxifen therapy for more than 1 year (Group III). When group III breast cancer patients were supplemented with CoRN for 45 days (Group IV) and 90 days (Group V) along with tamoxifen, a significant reduction in cytokine levels were observed (P < 0.05). Such a decrease in serum cytokine levels after CoRN supplementation in breast cancer patients may suggest good prognosis and efficacy of the treatment, and might even offer protection from metastases and recurrence of cancer.